How much is the osteosarcoma market worth, and how is it expected to expand?
The osteosarcoma market size has grown strongly in recent years. It will grow from $0.71 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increase in cancer awareness, improved treatment options, rise in incidences of bone cancer, rise in healthcare infrastructure, growth in research and clinical trials, and rise in development of targeted therapies and immunotherapies.
The osteosarcoma market size is expected to see strong growth in the next few years. It will grow to $0.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising adoption of personalized medicine, growing awareness of rare cancers, increasing government and private sector funding for research, rising incidence of genetic mutations, and rising potential for improved treatment outcomes with immunotherapy. Major trends in the forecast period include development of targeted therapies, advancements in immunotherapies, adoption of personalized medicine, advancements in gene editing techniques, innovation in chemotherapy drugs, improved diagnostic imaging technologies, and advancements in surgical techniques.
Get Your Free Sample of The Global Osteosarcoma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21239&type=smp
Which industry factors have accelerated the osteosarcoma market’s expansion?
The increasing prevalence of cancer is expected to propel the growth of the osteosarcoma market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade and destroy normal tissues. The rising cancer cases are due to factors such as aging population, lifestyle changes, environmental exposure, infections and genetic predisposition. Osteosarcoma treatment supports cancer patients by driving advancements in treatment strategies, fostering early detection techniques, and enhancing the understanding of bone cancer, which ultimately contributes to improved patient care, better survival outcomes, and the development of more effective therapies. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, reported that, in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide. Projections suggest these numbers could increase to 29.9 million new cases and 15.3 million deaths annually by 2040. Therefore, the increasing prevalence of cancer is driving the growth of osteosarcoma market.
What are the primary segments of the osteosarcoma market?
The osteosarcoma market covered in this report is segmented –
1) By Type: Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extraskeletal Osteosarcoma
2) By Treatment Type: Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy
3) By Age Group: Pediatric, Adult
4) By Distribution Channel: Online Channel, Offline Channel
5) By End User: Hospitals And Clinics, Diagnostic Centers, Academic And Research Organizations
Subsegments:
1) By Intramedullary Osteosarcoma: Metaphyseal Osteosarcoma, Diaphyseal Osteosarcoma
2) By Juxtacortical Osteosarcoma: Parosteal Osteosarcoma, Periosteal Osteosarcoma
3) By Extraskeletal Osteosarcoma: Primary Extraskeletal Osteosarcoma, Secondary Extraskeletal Osteosarcoma
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/osteosarcoma-global-market-report
Which firms are leading the osteosarcoma market?
Major companies operating in the osteosarcoma market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Hikma Pharmaceuticals PLC, Spectrum Pharmaceuticals Inc., Mylan N.V., Bellicum Phamaceuticals Inc., ADVAXIS Inc., Iovance Biotherapeutics Inc.
Which market trends are set to define the future of the osteosarcoma market?
Major companies operating in the osteosarcoma market are focusing on developing advanced drugs with orphan drug designation to enhance treatment efficacy, reduce side effects, and improve survival rates for patients. Orphan drug designation is a status given by regulatory agencies to drugs or biologics intended to treat rare diseases, providing benefits like tax credits, clinical trial assistance, and extended market exclusivity. For instance, in April 2024, Lisata Therapeutics Inc., a US-based pharmaceutical company, announced LSTA1 for treating osteosarcoma approved by the Food and Drug Administration (FDA), a US-based government agency granting orphan drug designation. LSTA1 is an investigational drug that activates a novel uptake pathway, enhancing drug penetration and accumulation in osteosarcoma tumors while potentially modifying the tumor microenvironment to improve responsiveness to immunotherapies.
Which geographic trends are shaping the osteosarcoma market, and which region has the highest market share?
North America was the largest region in the osteosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteosarcoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Osteosarcoma Market Report 2025 Offer?
The osteosarcoma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Osteosarcoma is a cancerous tumor that develops in the bone-forming cells, occurring in the long bones in the body. It mainly impacts teenagers and young adults, causing symptoms such as pain, swelling, and difficulty moving the affected area.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21239
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
